文献速递浆细胞疾病

帕比司他联合来那度胺和每周地塞米松治疗骨髓瘤的2期研究

A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma.
PubMed 文献 · Blood Adv · 2017-08-21

这项单中心2期研究纳入27例复发多发性骨髓瘤患者,其中22例(81%)来那度胺难治,17例(63%)存在高危分子学异常。总缓解率41%,临床获益率74%,疾病控制率96%,中位无进展生存期7.1个月,来那度胺难治患者中位无进展生存期6.5个月。

要点

  • 帕比司他联合来那度胺和地塞米松在来那度胺难治及高危患者中仍可见持久缓解。
  • 3/4级毒性主要为血液学毒性,未观察到显著胃肠道毒性。
  • MAGEA1 RNA和蛋白表达与短无进展生存期相关,可能为帕比司他耐药的生物标志物。

核心结论

  • 帕比司他联合来那度胺和地塞米松(FRD)在复发多发性骨髓瘤中产生持久缓解,包括高危和来那度胺难治患者,提示帕比司他在获得缓解中起关键作用。
  • MAGEA1表达可能代表帕比司他耐药的功能性生物标志物。
  • 与PANORAMA 1研究不同,FRD未出现显著胃肠道毒性,主要为预期的血液学毒性。

研究设计与样本

  • 单中心2期研究,评估帕比司他联合来那度胺和地塞米松(FRD)治疗复发多发性骨髓瘤。
  • 共纳入27例复发多发性骨髓瘤患者;22例(81%)为来那度胺难治,9例(33%)为难治性来那度胺、14例(52%)为硼替佐米难治、7例(26%)为卡非佐米难治。
  • 17例(63%)患者存在高危分子学异常。
  • 试验注册号为NCT00742027。

主要发现

  • 缓解包括2例完全缓解(CR)、4例非常好的部分缓解(VGPR)、5例部分缓解(PR)和9例微小缓解(MR),总缓解率41%,临床获益率74%,疾病控制率96%。
  • 中位无进展生存期(PFS)为7.1个月。
  • 在22例来那度胺难治患者中,有1例CR、4例VGPR、3例PR和7例MR,中位PFS为6.5个月。
  • 中位总生存期未达到。
  • 3/4级毒性主要为血液学毒性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Phase 3 studies combining histone deacetylase inhibitors with bortezomib were hampered by gastrointestinal (GI) intolerance, which was not observed when combined with immunomodulatory drugs. This study is a single-center phase 2 study of panobinostat with lenalidomide and dexamethasone (FRD). Twenty-seven relapsed multiple myeloma patients were enrolled. Twenty-two patients (81%) were lenalidomide refractory and 9 (33%), 14 (52%), and 7 (26%) were refractory to pomalidomide, bortezomib, and carfilzomib, respectively. High-risk molecular findings were present in 17 (63%) patients. Responses included 2 complete responses (CRs), 4 very good partial responses (VGPRs), 5 partial responses (PRs), and 9 minimal responses (MRs) for an overall response rate of 41%, clinical benefit rate of 74%, and a disease control rate of 96%. The median progression-free survival (PFS) was 7.1 months. In the 22 lenalidomide-refractory patients, there were 1 CR, 4 VGPRs, 3 PRs, and 7 MRs, with a median PFS of 6.5 months. Median overall survival was not reached. Grade 3/4 toxicities were primarily hematologic. Gene expression profiling of enrollment tumor samples revealed a set of 1989 genes associated with short (<90 days) PFS to therapy. MAGEA1 RNA and protein expression were correlated with short PFS, and laboratory studies demonstrated a role for MAGE-A in resistance to panobinostat-induced cell death. FRD demonstrates durable responses, even in high-risk, lenalidomide-refractory patients, indicating the essential role of panobinostat in attaining responses. MAGEA1 expression may represent a functional biomarker for resistance to panobinostat. In contrast to PANORAMA 1, there were no significant GI toxicities and primarily expected hematologic toxicities. This trial was registered at www.clinicaltrials.gov as #NCT00742027.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Chari A, Cho HJ, Dhadwal A, et al. A phase 2 study of panobinostat with lenalidomide and weekly dexamethasone in myeloma. Blood Adv. 2017. PMID: 29296798. doi:10.1182/bloodadvances.2017007427

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。